Search

Copyright of Journal of Clinical Nursing in Practice is the property of Journal of Clinical Nursing in Practice (Editorial Board, Shanghai Jiao Tong University Press) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To investigate the effects of rivaroxaban and low molecular weight heparin on the symptom relief, blood gas analysis indexes and coagulation function in elderly patients with acute exacerbation of chronic obstructive pulmonary disease（AECOPD）. Methods: A total of 72 elderly patients with AECOPD admitted to our hospital from August 2016 to November 2019 were selected, and were randomly divided into control group（n=36, low molecular weight heparin treatment） and study group（n=36,rivaroxaban treatment） by lottery. The efficacy, symptom relief, blood gas analysis index and coagulation function of the two groups were compared, and adverse reactions during the treatment were recorded. Results: The total effective rate of the study group 10 days after treatment was higher than the control group（P<0.05）. There were no significant differences in the relief time of cough, sputum, fever and dyspnea between the two groups（P>0.05）. 10 days after treatment, the oxygen partial pressure（PaO2）, oxygen saturation（SaO2） of the two groups increased, while the partial pressure of carbon dioxide（PaCO2） of the two groups decreased（P<0.05）. 10 days after treatment,PaO2 and SaO2 of the study group were higher than the control group, while PaCO2 was lower than those of the control group（P<0.05）.10 days after treatment, fibrinogen（Fib） of the two groups increased, D-Dimer（D-D）, activated partial thromboplastin time（APTT）,plasma prothrombin time（PT） and thrombin time（TT） decreased（P<0.05）. 10 days after treatment, D-D of the study group was lower than the control group（P<0.05）. There were no significant differences between Fib, APTT, TT and PT of the two groups（P>0.05）. There was no significant difference in the incidence of adverse reactions between the two groups（P>0.05）. Conclusion: Elderly patients with AECOPD treated with rivaroxaban and low molecular weight heparin can improved their clinical symptoms and showed better safety, but those treated with rivaroxaban had better efficacy, and better improvement in blood gas analysis indicators and coagulation function. [ABSTRACT FROM AUTHOR]

Objective: To explore the clinical effect of Maxingshigan decoction and Qianjinweigan decoction plus combined with western medicine in the treatment of patients with lung syndrome of phlegm heat stagnation in acute exacerbation of chronic obstructive pulmonary disease (COPD) and the influence on lung function and serum inflammatory factors. Methods: From January 2018 to December 2018, 80 patients with lung syndrome of phlegm heat stagnation in acute exacerbation of COPD were selected, they were randomly divided into two groups, 40 cases in each group. The observation group was treated with Maxingshigan decoction and Qianjinweigan decoction for 7 days on the basis of conventional western medicine treatment, the control group was treated with conventional western medicine for 7 days. The lung function indexes, serum inflammatory factors and modified British Medical Research Association dyspnea index (mMRC) scores of the two groups before and after treatment were recorded and the clinical effects of the two groups were compared. Results: Forced vital capacity (FVC) and forced expiratory volume in the first second/FVC (FEV1 / FVC) of the two groups were improved after treatment compared with before treatment, but there was no significant difference between the observation group and the control group(P>0.05). The levels of serum C-reactive protein (CRP) and tumor necrosis factor-琢 (TNF-琢) in the two groups were significantly improved after treatment compared with before treatment, the level of serum TNF-琢 was lower in the observation group(P<0.05). The mMRC score of the observation group was significantly lower than that of the control group after treatment(P<0.05). In term of total efficiency, the observation group and the control group was 80.00% and 72.50% respectively, there was no significant difference between the two groups (P>0.05). In term of apparent efficiency, the observation group is better than the control group, the difference was statistically significant(P<0.05). Conclusion: Maxingshigan decoction and Qianjinweigan decoction plus combined with western medicine treat patients with lung syndrome of phlegm heat stagnation in acute exacerbation of COPD can obviously improve breathing difficulties, cough cough sputum and other symptoms, reduce serum TNF-琢 level, thereby increase the apparent efficiency. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Clinical Healthcare is the property of Chinese Journal of Clinical Healthcare and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)